| 1 |
34463438 | Bioactive compounds from Matricaria chamomilla: structure identification, in vitro antiproliferative, antimigratory, antiangiogenic, and antiadenoviral activities. | 2022 Mar 28 |
1 |
| 2 |
34596910 | Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. | 2022 Jan |
2 |
| 3 |
34862634 | Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. | 2022 Feb |
2 |
| 4 |
34862655 | Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors. | 2022 Feb |
4 |
| 5 |
35091289 | Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold. | 2022 Mar |
1 |
| 6 |
35123995 | Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism. | 2022 Mar 1 |
1 |
| 7 |
35189405 | Nitric oxide in multikinase inhibitor-induced hand-foot skin reaction. | 2022 Jul |
2 |
| 8 |
35245519 | Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk. | 2022 May 15 |
5 |
| 9 |
35337128 | Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability. | 2022 Mar 9 |
2 |
| 10 |
35445315 | Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. | 2022 Jun |
2 |
| 11 |
35457095 | In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology. | 2022 Apr 12 |
1 |
| 12 |
35484400 | KDR genetic predictor of toxicities induced by sorafenib and regorafenib. | 2022 Apr 28 |
1 |
| 13 |
35489270 | Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation. | 2022 Jul |
1 |
| 14 |
35496328 | Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFRT790M tyrosine kinase inhibitors. | 2022 Apr 22 |
1 |
| 15 |
33334586 | Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. | 2021 Feb |
1 |
| 16 |
33349069 | Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation. | 2021 Dec |
1 |
| 17 |
33628103 | LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. | 2021 |
1 |
| 18 |
33667419 | Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity. | 2021 Jun |
1 |
| 19 |
33831675 | Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines. | 2021 Jul |
1 |
| 20 |
33917617 | Aryl Urea Based Scaffolds for Multitarget Drug Discovery in Anticancer Immunotherapies. | 2021 Apr 6 |
1 |
| 21 |
33944931 | Study on novel PtNP-sorafenib and its interaction with VEGFR2. | 2021 Oct 12 |
1 |
| 22 |
33948974 | Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review. | 2021 Jul |
1 |
| 23 |
33962153 | Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. | 2021 Jun 15 |
1 |
| 24 |
34056992 | Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. | 2021 Dec |
1 |
| 25 |
34089726 | Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. | 2021 Sep 1 |
1 |
| 26 |
34108938 | Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer. | 2021 |
1 |
| 27 |
34175720 | Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. | 2021 Sep |
2 |
| 28 |
34325596 | Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies. | 2021 Dec |
1 |
| 29 |
34340610 | Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. | 2021 Dec |
1 |
| 30 |
34411344 | Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. | 2021 Nov |
1 |
| 31 |
34460053 | Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. | 2021 Aug 30 |
1 |
| 32 |
34534755 | Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2. | 2021 Nov |
3 |
| 33 |
34582293 | Predictive biomarkers for systemic therapy of hepatocellular carcinoma. | 2021 Nov |
1 |
| 34 |
34591285 | Donafenib: First Approval. | 2021 Nov |
1 |
| 35 |
34655447 | ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology. | 2021 Nov |
1 |
| 36 |
34691254 | Sorafenib treatment of metastatic melanoma with c-Kit aberration reduces tumor growth and promotes survival. | 2021 Dec |
2 |
| 37 |
34853223 | Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions. | 2021 |
1 |
| 38 |
34876355 | Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. | 2021 Dec 4 |
1 |
| 39 |
34909649 | Reversal of TGF-β-induced epithelial-mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor. | 2021 |
2 |
| 40 |
32065066 | Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound. | 2020 Jan-Dec |
1 |
| 41 |
32399432 | Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. | 2020 Apr |
2 |
| 42 |
32480170 | Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors. | 2020 Aug |
2 |
| 43 |
32510731 | Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors. | 2020 Aug |
1 |
| 44 |
32549224 | Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. | 2020 Jun 15 |
1 |
| 45 |
32653608 | Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme. | 2020 Sep |
1 |
| 46 |
32663641 | Synthesis and biological evaluation of diaryl urea derivatives designed as potential anticarcinoma agents using de novo structure-based lead optimization approach. | 2020 Sep 1 |
1 |
| 47 |
32683176 | Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation. | 2020 Sep |
2 |
| 48 |
32747013 | Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. | 2020 Oct |
1 |
| 49 |
32882995 | Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. | 2020 Sep 1 |
1 |
| 50 |
33142416 | Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. | 2020 Nov |
1 |